1987
Developmental therapeutics and the acquired immunodeficiency syndrome.
DeVita V, Broder S, Fauci A, Kovacs J, Chabner B. Developmental therapeutics and the acquired immunodeficiency syndrome. Annals Of Internal Medicine 1987, 106: 568-81. PMID: 2435201, DOI: 10.7326/0003-4819-106-4-568.Peer-Reviewed Original ResearchConceptsHuman T-lymphotropic virus type IIIPotential screening targetsTreatment of AIDST4 subsetOverwhelming infectionImmunodeficiency syndromeOpportunistic infectionsDevelopmental therapeuticsImmune competenceAntiviral drugsViral DNA polymeraseScreening targetsType IIIInfectionAIDSViral integrationDrugsSpecific targetsEncouraging resultsPatientsSyndromeLymphocytes
1984
25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE
DeVita V, Goidin A. 25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE. 1984, 499-526. DOI: 10.1016/b978-0-12-667980-9.50032-4.Peer-Reviewed Original ResearchCombination of drugsTypes of tumorsNational Cancer InstituteGroup of diseasesDosage scheduleCancer therapistClinical oncologistsCancer InstituteExperimental animalsBeneficial effectsTherapeutic researchTumorsDrugsTreatmentSignificant numberField of medicineRemissionChemotherapyPatientsSurgeryOncologistsRadiotherapyCancerDiseasePhysicians
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answer
1978
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1973
Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man
Sponzo R, Devita V, Oliverio V. Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man. Cancer 1973, 31: 1154-1159. PMID: 4705152, DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b.Peer-Reviewed Original Research
1970
Pentamidine: Clinical pharmacologic correlations in man and mice
Waalkes T, Denham C, DeVita V. Pentamidine: Clinical pharmacologic correlations in man and mice. Clinical Pharmacology & Therapeutics 1970, 11: 505-512. PMID: 5310706, DOI: 10.1002/cpt1970114505.Peer-Reviewed Original ResearchConceptsDiffuse interstitial pneumoniaInterstitial pneumoniaUrinary excretionPlasma levelsPneumocystis cariniiSingle intraperitoneal injectionTypes of pneumoniaDosage scheduleCancer patientsMalignant diseaseRenal abnormalitiesConcomitant useIntraperitoneal injectionIntramuscular administrationOrgan transplantationExcretion patternsPatientsPneumoniaPentamidineExcretionDrugsMenDiseaseMiceCarinii
1967
The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals
DeVita V, Denham C, Davidson J, Oliverio V. The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals. Clinical Pharmacology & Therapeutics 1967, 8: 566-577. PMID: 4951973, DOI: 10.1002/cpt196784566.Peer-Reviewed Original Research